TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01943565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 25mcg
Description: Intrathecal Hydromorphone 25mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 50mcg
Description: Intrathecal Hydromorphone 50mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 100mcg
Description: Intrathecal Hydromorphone 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: bupivacaine 0.75% 1.6 mL (12mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: bupivacaine 0.75% 1.6 mL (12mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: bupivacaine 0.75% 1.6 mL (12mg)
Study: NCT04941196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag (Ticagrelor 90 mg)
Description: Ticagrelor 90 mg Immediate Release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilinta (Ticagrelor 90 mg)
Description: Ticagrelor 90 mg Immediate Release tablet
Study: NCT01870739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696)
Description: 200 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo to sacubitril/valsartan (LCZ696)
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo to olmesartan
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine (Optional)
Description: If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine (Optional)
Description: If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
Study: NCT03033771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation with the Multilayer Flow Modulator (MFM)
Description: Endovascular implantation with the MFM
Study: NCT02608918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Study: NCT00584961

Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional
Study: NCT00317460

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physician Management
Description: Standard physician care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Physician Management and Counseling
Study: NCT01019785

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 100 000 U drops is given once

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Ergocalciferol
Description: 500 U drops given once
Study: NCT02436603

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition/Mind-Body Coaching
Description: Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
Study: NCT01565980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: symptom assessment
Description: attention control receives a weekly symptom assessment phone interview for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: symptom assessment
Description: attention control receives a weekly symptom assessment phone interview for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
Study: NCT02944019

Intervention type: DRUG
Intervention: Edoxaban
Description: Prescribed according to approved label
Study: NCT01923688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informatics Alert/Nurse/physician responders
Study: NCT03275545

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is being examined in this study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is being examined in this study
Study: NCT02425098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)
Description: High-dose TDV subcutaneous injection
Study: NCT04957381

Intervention type: BEHAVIORAL
Intervention: Group exercises
Description: Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.

Intervention type: BEHAVIORAL
Intervention: Group exercises
Description: Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.

Intervention type: BEHAVIORAL
Intervention: Group exercises
Description: Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.

Intervention type: BEHAVIORAL
Intervention: Group exercises
Description: Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.

Intervention type: BEHAVIORAL
Intervention: Group exercises
Description: Group exercises including aerobic, resistance and stretching exercise. Once a week for 8-12 weeks.
Study: NCT04888663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Ramucirumab + Paclitaxel
Description: For both Phase Ib and II: Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg on Days 1, 8, 15 and 22, and ramucirumab 8 mg/kg on Days 1 and 15, as well as paclitaxel will be administered intravenously in a 4-week cycle (every 28 days) For Phase Ib, Paclitaxel 80 or 70 mg/m2 (according to dose level) will be administered on Days 1, 8, 15 For Phase II, paclitaxel at RP2D (80 or 70 mg/m2) will be administered on Days 1, 8, 15 of each cycle
Study: NCT03834532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast reconstruction decision aid
Description: The breast reconstruction decision aid is a web-based, interactive tool that participants will use after the first breast surgery visit and before a plastic surgery visit or surgery. The decision aid provides information about post-mastectomy breast reconstruction and helps the participant clarify their preferences related to the procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational website
Description: The educational website contains information on healthy living with breast cancer including, physical activity and nutrition.
Study: NCT01273545

Intervention type: DRUG
Intervention: PRILIGY (dapoxetine hydrochloride)
Description: The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
Study: NCT03883737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNM
Description: an asymmetric rectangular biphasic current (250 microseconds, 10 Hz)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNM
Description: an asymmetric rectangular biphasic current (250 microseconds, 10 Hz)
Study: NCT00054587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 500 mg/m², D1 and every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m², D1 and every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 100 mg/m², D1 and every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 500 mg/m², D1 and every 3 weeks
Study: NCT01608035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic catheter
Description: presurgical sciatic catheter insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stump catheter
Description: intraoperative placed stump catheter
Study: NCT04336904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction
Study: NCT03136107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiogel Daily Defence Protective Day Cream Light
Description: Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ISO 24444:2010 P3 Standard Sunscreen
Description: Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
Study: NCT03502720

Intervention type: DEVICE
Intervention: Scaphoid fixation using 3D device
Description: A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner using a customised 3D exoesqueleton guide

Intervention type: PROCEDURE
Intervention: Scaphoid fixation using standard procedure
Description: A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner without using the 3D device (standard procedure)
Study: NCT04557280

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: A single subcutaneous injection of 16 mg.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: A single subcutaneous injection of 16 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: A single subcutaneous injection of 16 mg.
Study: NCT02380755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: 50 mg orally daily during 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill orally daily during 12 weeks
Study: NCT01500837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: association of RIFAMPIN + CLINDAMYCIN
Description: association of RIFAMPIN + CLINDAMYCIN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: association of LEVOFLOXACIN+ CLINDAMYCIN
Description: association of LEVOFLOXACIN+ CLINDAMYCIN
Study: NCT04405960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 1 MCG Oral Capsule
Description: The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
Study: NCT03280251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogniPlus software
Description: Structured cognitive training with CogniPlus software, twice per week during 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CogniPlus software
Description: Structured cognitive training with CogniPlus software, twice per week during 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pseudo cognitive training
Description: Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pseudo cognitive training
Description: Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
Study: NCT01041248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8mg/kg every 2 weeks i.v.
Study: NCT00875069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
Study: NCT04394442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg BD first day then 200 mg BD for 5 days
Study: NCT01901094

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Axillary Lymph Node Dissection (ALND)

Intervention type: RADIATION
Group type: OTHER
Intervention: Nodal Radiation Therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Nodal Radiation Therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Axillary Radiation Therapy
Study: NCT04532710

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eye Drops, Solution in Single-Dose Container
Description: Application of eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eye Drops, Solution in Single-Dose Container
Description: Application of eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drops, Solution in Single-Dose Container
Description: Application of eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drops, Solution in Single-Dose Container
Description: Application of eye drops
Study: NCT03213301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: 3.2 mg/m2 i.v. every 3 weeks
Study: NCT03050983

Intervention type: DEVICE
Intervention: IPI
Description: Enable the IPI algorithm and IPI alarm algorithm
Study: NCT00836355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 2 (or 3) intravenous doses, the first on study entry, the last 24 hours later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg orally once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg orally once daily for 5 days
Study: NCT02404103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flunisolide HFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flunisolide HFA
Study: NCT02596659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Description: Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham shockwave therapy
Description: Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Physical therapy
Description: The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
Study: NCT02796573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioural therapy
Study: NCT03194815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: This is a blood product containing antibodies from thousands of healthy donors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the control, or sham, treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
Study: NCT03597165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incidental Genomic Sequencing Results
Description: Patient will receive GS results related to their primary indication (cancer), as well as the option to learn incidental GS results. Incidental results will be categorized into five bins based on Berg et al.'s framework (medically actionable and pharmacogenetic, common disease SNPs, Mendelian conditions, early-onset brain diseases, and carrier status). In pre-test counseling, patients will have the option to select which bins of incidental results they would like to learn, if any.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GS Results for Primary Indications only
Description: Patients will receive GS results related to the primary indication (cancer) only.
Study: NCT01469910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simotinib Hydrochloride
Description: Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
Study: NCT00930059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: tablets, 25 mg every 12 hours for 12 wks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets, every 12 hours for 12 wks